JACOBS LEVY EQUITY MANAGEMENT, INC

Position in TRDA — Entrada Therapeutics, Inc.

CIK 884414 FLORHAM PARK, NJ

Position in TRDA

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$2,233,458

-$1,980,536 QoQ

Shares Held

303,459

-9.1% QoQ

Ownership

0.779%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#20

of 128 holders

Holding Since

Jun 2024

9 quarters on record

Voting authority Sole 77% Shared 0% None 23%

Healthcare · as of Jun 30, 2026

JACOBS LEVY EQUITY MANAGEMENT, INC holds $741,570,791 across 81 Biotechnology names. TRDA ranks #42 (0.3% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	REGN	Regeneron Pharmaceuticals, Inc.	256,503	$159,939,880
2	RARE	Ultragenyx Pharmaceutical Inc.	2,939,719	$98,157,217
3	INCY	Incyte Corp	731,774	$82,953,900
4	CORT	Corcept Therapeutics Inc	695,532	$60,476,507
5	HALO	Halozyme Therapeutics, Inc.	322,377	$25,232,447
6	EXEL	Exelixis, Inc.	415,650	$22,615,516
7	AUPH	Aurinia Pharmaceuticals Inc.	1,231,516	$20,898,826
8	ALNY	Alnylam Pharmaceuticals, Inc.	60,986	$18,358,615

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$2,233,458	303,459	-9.1%	Shares	Sole	2026-08-14
2026-03-31	$4,213,994	333,914	-8.0%	Shares	Sole	2026-05-15
2025-12-31	$3,729,440	362,786	+14.9%	Shares	Sole	2026-02-13
2025-09-30	$1,831,698	315,810	+43.1%	Shares	Sole	2025-11-17
2025-06-30	$1,483,345	220,736	+4.7%	Shares	Sole	2025-08-14
2025-03-31	$1,906,291	210,873	-0.9%	Shares	Sole	2025-05-15
2024-12-31	$3,677,876	212,717	+5.4%	Shares	Sole	2025-02-14
2024-09-30	$3,224,811	201,803	+50.3%	Shares	Sole	2024-11-14
2024-06-30	$1,912,977	134,244	—	Shares	Sole	2024-08-14
No filing history on record for this holder in this stock.